$Eisbach Bio doses first patient in Phase 1/2 Trial for first-in-class drug to take on Refractory Advanced Solid Tumors$

Mukul Verma 9/16/24 Mukul Verma 9/16/24

Eisbach Bio doses first patient in Phase 1/2 Trial for first-in-class drug to take on Refractory Advanced Solid Tumors

The trial is being conducted at The University of Texas MD Anderson Cancer Center and is co-funded by Cancer Focus Fund.

Mukul Verma 3/21/24 Mukul Verma 3/21/24

Cancer Focus Fund invests $4.5 million in Eisbach Bio

Cancer Focus Fund is investing $4.5 million to support a Phase 1/2 clinical trial of Eisbach’s Bio lead candidate, EIS-12656, which will be conducted at MD Anderson. The drug candidate targets hard-to-treat tumors.